Improvement in dermatomyositis rash associated with the use of antiestrogen medication

Archives of Dermatology

Volumn 142, Issue 1, 2006, Pages 70-72

  Sereda, Danya ^a   Werth, Victoria P ^b,c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Department of Dermatology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; HYDROXYCHLOROQUINE; PREDNISONE; TAMOXIFEN;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; DERMATOMYOSITIS; FEMALE; HUMAN; HUMAN TISSUE; LABORATORY TEST; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RASH; SKIN BIOPSY; THORAX RADIOGRAPHY;

ADULT; BIOPSY; BREAST NEOPLASMS; DERMATOMYOSITIS; DIAGNOSIS, DIFFERENTIAL; ESTROGEN ANTAGONISTS; EXANTHEMA; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITRILES; SKIN; TAMOXIFEN; TRIAZOLES;

EID: 30844471764     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.1.70     Document Type: Article

References (29)

1. Yazici Y, Kagen LJ. Clinical presentation of the idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 2002;28:823-832.
2. Sontheimer RD. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin. 2002;20:387-408.
3. Mendez EP, Lipton R, Ramsey-Goldman R, et al. US incidence of juvenile dermatomyositis, 1995-1998. Arthritis Rheum. 2003;49:300-305.
4. Mebazaa A, Boussen H, Nouira R, et al. Dermatomyositis and malignancy in Tunisia. J Am Acad Dermatol. 2003;48:530-534.
5. Jacobson JD, Ansari MA. Immunomodulatory actions of gonadal steroids may be mediated by gonadotropin-releasing hormone. Endocrinology. 2004;145:330-336.
6. Sthoeger ZM, Zinger H, Mozes E. Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZBxNZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies. Ann Rheum Dis. 2003;62:341-346.
7. Cutolo M, Villaggio B, Craviotto C, Pizzorni C, Seriolo B, Sulli A. Sex hormones and rheumatoid arthritis. Autoimmun Rev. 2002;1:284-289.
8. Doria A, Cutolo M, Ghirardello A, et al. Steroid hormones and disease activity during pregnancy in systemic lupus erythematosus. Arthritis Rheum. 2002;47:202-209.
9. Werth VP, Zhang W. Wavelength-specific synergy between ultraviolet radiation and interleukin-1 alpha in the regulation of matrix-related genes: mechanistic role for tumor necrosis factor alpha. J Invest Dermatol. 1999;113:196-201.
10. Werth VP, Callen JP, Ang G, Sullivan KE. Associations of tumor necrosis factor α and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis. J Invest Dermatol. 2002;119:617-620.
11. De Bleecker JL, Meire VI, Declercq W, Van Aken EH. Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord. 1999;9:239-246.
12. Pachman LM, Liotta-Davis MR, Hong DK, et al. TNFalpha-308A allele in juvenile dermatomyositis. Arthritis Rheum. 2000;43:2368-2377.
13. Fedczyna TO, Lutz J, Pachman LM. Expression of TNFalpha by muscle fibers in biopsies from children with untreated juvenile dermatomyositis: association with the TNFalpha-308A allele. Clin Immunol. 2001;100:236-239.
14. Kuru S, Inukai A, Liang Y, Doyu M, Takano A, Sobue G. Tumor necrosis factoralpha expression in muscles of polymyositis and dermatomyositis. Acta Neuropathol (Berl). 2000;99:585-588.
15. O'Regan RM, Jordan VC. The evolution of tamoxifen therapy in breast cancer. Lancet Oncol. 2002;3:207-214.
16. Cosman F. Selective estrogen-receptor modulators. Clin Geriatr Med. 2003;19:371-379.
17. McDonnell DP, Wijayaratne A, Chang C, Norris JD. Elucidation of the molecular mechanism of action of selective estrogen receptor modulators. Am J Cardiol. 2002;90:35F-45F.
18. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy pre-menopausal and postmenopausal women. J Clin Oncol. 1996;14:78-84.
19. Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer. J Natl Cancer Inst. 1998;90:1371-1388.
20. Allred DC, Baum M, Buzdar AU, et al. Dilemmas in breast disease. Breast J. 2003;9:213-222.
21. Nelson LR, Bulun SE. Estrogen production and action. J Am Acad Dermatol. 2001;45(3, suppl):S116-S124.
22. Dowsett M. Origin and characteristics of adverse events in aromatase inhibition therapy for breast cancer. Semin Oncol. 2003;30:58-69.
23. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Cancer. 2003;98:1802-1810.
24. Carruba G, D'Agostino P, Miele M, et al. Estrogen regulates cytokine production and apoptosis in PMA-differentiated, macrophage-like U937 cells. J Cell Biochem. 2003;90:187-196.
25. Lilli C, Marinucci L, Bellocchio S, et al. Effects of transforming growth factor-beta1 and tumour necrosis factor-alpha on cultured fibroblasts from skin fibroma as modulated by toremifene. Int J Cancer. 2002;98:824-832.
26. Nzeusseu A, Durez P, Houssiau F, Devogelaer J. Successful use of infliximab in a case of refractory juvenile dermatomyositis [abstract]. Arthritis Rheum. 2001;44:S40.
27. Hengstman GJD, van den Hoogen FHJ, Barrera P, et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol. 2003;50:10-15.
28. Hengstman GJ, van den Hoogen FH, van Engelen BG. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up. Eur Neurol. 2004;52:61-63. Medline:15240986.
29. Fairlamb D, Boesen E. Gynecomastia associated with gonadotropin-secreting carcinoma of the lung. Postgrad Med J. 1977;53:269-271.